CCL17 was initially isolated from phytohemagglutinin-stimulated PBMCs. CCL17 is constitutively expressed in thymus and, upon activation, in several cell types. CCL17-mediated recruitment of Th2 cells and CLA+ CD4+ T cells and play key roles in allergic diseases like atopic dermatitis, allergic asthma, allergic rhinitis, and allergic contact dermatitis. In addition, CCL17 has been detected in idiopathic pulmonary fibrosis. CCL17 and CCL22 secreted by DCs seem to mediate the recruitment of Tregs to sites of inflammation in patients with chronic hepatitis. In addition, CCL17 is present in advanced human and mouse atherosclerosis, and CCL17+ DCs accumulate in atherosclerotic lesions. CCL17 expressed by DCs limit the expansion of Tregs. CCL17 is upregulated by a combination of cytokines (TNFa, IL-4, and IFNγ) in bronchial epithelial cells; TGFβ1, TNFα, and IFNγ in the human keratinocyte cell line; and histamine and prostaglandin E2P in immature DC.

PRODUCT DETAILS

Clone: A20096E.Rec

Antibody Type: Recombinant

Reactivity: Mouse

Format: CCL17

Host: Rat

Isotype: IgG2b, κ

Applications: ICFC - Quality tested

Regulatory Status: RUO

Data Sheets: TDS | SDS

Note to Purchaser: This product is manufactured and supplied by BioLegend, Inc. under an agreement between BioLegend, Inc. and Cytek Biosciences, Inc. Information related to this product is provided by BioLegend, Inc.